详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Immunotoxin Therapy for Lung Cancer

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C ◇ 中华系列

作者：

单位： [1]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China [2]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China [3]Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA [4]Department of Medicine, China‑Japan Friendship Hospital, Beijing 100029, China

出处：

DOI：

ISSN：

关键词： Immunotherapy Immunotoxins Lung Neoplasms Molecular Targeted Therapy

基金：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2016]版：

大类 | 4 区医学

小类 | 4 区医学：内科

最新[2025]版：

大类 | 2 区医学

小类 | 2 区医学：内科

JCR分区：

出版当年[2015]版：

Q3 MEDICINE, GENERAL & INTERNAL

最新[2023]版：

Q1 MEDICINE, GENERAL & INTERNAL

影响因子： 最新[2023版] 7.5 最新五年平均[2021-2025] 4.9 出版当年[2015版] 0.957 出版当年五年平均[2011-2015] 1.017 出版前一年[2014版] 1.053 出版后一年[2016版] 1.064

第一作者：

第一作者单位： [1]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China [2]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China [*1]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

通讯作者：

通讯机构： [1]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China [2]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China [*1]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]肾癌的分子靶向治疗 [2]胰腺癌精准治疗的研究进展 [3]食管胃结合部腺癌分子靶向治疗的研究进展 [4]Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements [5]Apatinib plus S-1 for previously treated, advanced gastric or gastro-oesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study [6]Addition of docosahexaenoic acid synergistically enhances the efficacy of apatinib for triple-negative breast cancer therapy [7]Traditional Chinese medicine Astragalus polysaccharide enhanced antitumor effects of the angiogenesis inhibitor apatinib in pancreatic cancer cells on proliferation, invasiveness, and apoptosis [8]Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study [9]DNT Cell-based Immunotherapy: Progress and Applications [10]Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC)